FDA par­tial­ly halts Nurix Ther­a­peu­tics’ can­cer tri­al as it im­proves man­u­fac­tur­ing process

The FDA is paus­ing pa­tient en­roll­ment and screen­ing for Nurix Ther­a­peu­tics’ Phase I clin­i­cal tri­al for a po­ten­tial drug to treat B-cell ma­lig­nan­cies in can­cer pa­tients.

The agency is halt­ing the tri­al af­ter Nurix told the FDA it is im­prov­ing the man­u­fac­tur­ing process of the po­ten­tial drug, known as NX-2127, which is a de­grad­er of BTK and IMiD neo­sub­strates.

Nurix is in com­mu­ni­ca­tion with the FDA to “in­tro­duce the im­proved NX-2127 man­u­fac­tur­ing process and drug prod­uct in­to our clin­i­cal de­vel­op­ment plan,” CEO Arthur Sands said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER